Zenoxa Oral Suspension contains Oxcarbazepine 300mg/5ml, an anticonvulsant medication indicated for the treatment of partial seizures and epilepsy in both adults and pediatric patients. Oxcarbazepine acts by stabilizing hyperexcited neural membranes, inhibiting repetitive neuronal firing, and reducing the propagation of seizure activity through blockade of voltage-sensitive sodium channels. This suspension formulation allows for flexible dosing in patients who have difficulty swallowing tablets or require precise dose adjustments. Zenoxa Oral Suspension is administered orally and should be taken consistently with or without food to maintain steady plasma concentrations. Dosage must be individualized based on clinical response and tolerability, with careful titration to minimize adverse effects. Common side effects may include dizziness, somnolence, headache, nausea, and hyponatremia; therefore, regular monitoring of serum sodium levels is recommended during therapy. Caution is advised in patients with a history of hypersensitivity to carbamazepine or related compounds, and potential drug interactions should be assessed prior to initiation. Zenoxa Oral Suspension provides an effective therapeutic option for seizure management, improving compliance and quality of life in patients requiring antiepileptic treatment.